Drug Trial Radar · NCT05359211
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Dec 8, 2022
Primary completion
Sep 4, 2025
Study completion Sep 4, 2026
Sponsor
- Lead sponsor
- Fred Hutchinson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Nektar Therapeutics
- First posted
- May 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase Ib trial studies the effects of NKTR-255 in combination with chimeric antigen (CAR)-T cell therapy and to see how well they work in treating patients with large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. T cells are infection fighting blood cells that can kill tumor cells. Lisocabtagene maraleucel is a CAR-T cell product that consists of genetically engineered T cells, modified to recognize CD19, a protein on the surface of cancer cells. These CD19-specific T cells may help the body's immune system identify and kill CD19-positive cancer cells. Giving NKTR-255 together with lisocabtagene maraleucel may work better in treating large B-cell lymphoma than either drug alone.
Conditions
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Grade 3b Follicular Lymphoma
- Recurrent Primary Mediastinal Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory Grade 3b Follicular Lymphoma
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
CyclophosphamideDrug
Given IV
FludarabineDrug
Given IV
Lisocabtagene MaraleucelBiological
Given IV
Polymer-conjugated IL-15 Receptor Agonist NKTR-255Drug
Given IV
X-Ray ImagingProcedure
Undergo x-ray imaging
EchocardiographyProcedure
Undergo ECHO
Multigated Acquisition ScanProcedure
Undergo MUGA
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy and aspiration
Bone Marrow AspirationProcedure
Undergo bone marrow biopsy and aspiration
Lumbar PunctureProcedure
Undergo LP
Computed TomographyProcedure
Undergo PET/CT
Positron Emission TomographyProcedure
Undergo PET/CT
Biospecimen CollectionProcedure
Undergo blood and CSF sample collection
BiopsyProcedure
Undergo tissue biopsy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: 30 days after the last dose of NKTR-255 or until a new antitumor therapy has been initiated
- Dose-limiting toxicity (DLT) ratesTime frame: Up to 21 days after the first NKTR-255 infusion
- Optimal biological dose (OBD)Time frame: Up to 12 months after the CAR-T cell infusion
- Complete response (CR) rateTime frame: Up to 3 months after the CAR-T cell infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.